Fox Run Management, L.L.C. Corcept Therapeutics Inc Transaction History

Fox Run Management, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 07, 2023	BUY	$21.97 - $33.8 $177,627 - $273,273	8,085 New	8,085 $220,000
Q4 2022 Feb 07, 2023	BUY	$19.95 - $29.96 $589,123 - $884,718	29,530 New	29,530 $599,000
Q4 2018 Jan 15, 2019	SELL	$11.29 - $17.19 $169,519 - $258,107	-15,015 Closed	0 $0
Q3 2018 Oct 05, 2018	BUY	$12.27 - $15.65 $184,234 - $234,984	15,015 New	15,015 $211,000

355

86.2M

1.12M

667K

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $7.17B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Fox Run Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Fox Run Management, L.L.C. with notifications on news.